Show simple item record

dc.contributor.authorSchmidt, Henri
dc.contributor.authorKulasinghe, Arutha
dc.contributor.authorAllcock, Richard JN
dc.contributor.authorTan, Lit Yeen
dc.contributor.authorMokany, Elisa
dc.contributor.authorKenny, Liz
dc.contributor.authorPunyadeera, Chamindie
dc.date.accessioned2022-02-07T05:51:42Z
dc.date.available2022-02-07T05:51:42Z
dc.date.issued2018
dc.identifier.issn2075-4418
dc.identifier.doi10.3390/diagnostics8040079
dc.identifier.urihttp://hdl.handle.net/10072/412084
dc.description.abstractBACKGROUND: PIK3CA pathways are the most frequently mutated oncogenic pathway in head and neck squamous cell carcinoma (HNSCC), including virally driven HNCs. PIK3CA is involved in the PI3K-PTEN-mTOR signalling pathway. PIK3CA has been implicated in HNSCC progression and PIK3CA mutations may serve as predictive biomarkers for therapy selection. Circulating tumour DNA (ctDNA) derived from necrotic and apoptotic tumour cells are thought to harbour tumour-specific genetic alterations. As such, the detection of PIK3CA alterations detected by ctDNA holds promise as a potential biomarker in HNSCC. METHODS: Blood samples from treatment naïve HNSCC patients (n = 29) were interrogated for a commonly mutated PIK3CA hotspot mutation using low cost allele-specific Plex-PCRTM technology. RESULTS: In this pilot, cross sectional study, PIK3CA E545K mutation was detected in the plasma samples of 9/29 HNSCC patients using the Plex-PCRTM technology. CONCLUSION: The results of this pilot study support the notion of using allele-specific technologies for cost-effective testing of ctDNA, and further assert the potential utility of ctDNA in HNSCC.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherMDPI
dc.relation.ispartofpagefrom79
dc.relation.ispartofissue4
dc.relation.ispartofjournalDiagnostics
dc.relation.ispartofvolume8
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3211
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsMedicine, General & Internal
dc.subject.keywordsGeneral & Internal Medicine
dc.subject.keywordscirculating tumour (ctDNA)
dc.titleA Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationSchmidt, H; Kulasinghe, A; Allcock, RJN; Tan, LY; Mokany, E; Kenny, L; Punyadeera, C, A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer, Diagnostics, 2018, 8 (4), pp. 79
dcterms.dateAccepted2018-11-26
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2022-02-07T05:48:15Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorPunyadeera, Chamindie


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record